Results 111 to 120 of about 150,085 (313)

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

The pharmacology of statins

Pharmacological Research, 2014
Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are molecules of fungal origin. By inhibiting a key step in the sterol biosynthetic pathway statins are powerful cholesterol lowering medications and have provided outstanding contributions to the prevention of cardiovascular disease. Their detection in mycetes traces back
openaire   +2 more sources

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, EarlyView.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Statins [PDF]

Vascular Medicine, 2017
Elizabeth V, Ratchford, Seth S, Martin
openaire   +2 more sources

"Who receives statins? Variations in physicians’ prescribing patterns for patients with coronary heart disease, dyslipidemia, and diabetes" [PDF]

Our objective is to estimate the extent to which clinical and non-clinical factors are associated with physicians’ prescribing patterns for statins. The data are from the National Ambulatory Medical Care Survey for the period 1992 through 2004. The three
Simon Condliffe, Charles R. Link, Bryan Townsend   +2 more
core  

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, EarlyView.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Genome-wide study of gene variants associated with differential cardiovascular event reduction by Pravastatin therapy [PDF]

, 2012
Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood.
Westendorp, Rudi G. J., Louie Judy Z., Packard, C., Rudi G. J. Westendorp, Louie, Judy Z., Olga A. Iakoubova, Trompet, S., David J. Stott, Ian Ford, Ford Ian, Slagboom, P. Eline, Judy Z. Louie, Sacks Frank M., David J Stott, Iakoubova Olga A., Westendorp Rudi G. J., Stott, D., Trompet, Stella, Buckley, B.M., P Eline Slagboom, Dov Shiffman, Charles M Rowland, Buckley Brendan M., Sacks, Frank, Craen, A.J.M. de, Iakoubova, Olga A., Shiffman, D., Rowland, Charles M., Devlin, James J., Frank M. Sacks, Stella Trompet, Catanese, J.J., Anton J M de Craen, de Craen Anton J. M., Naveed Sattar, Joseph J Catanese, Brendan M. Buckley, Ford, Ian, Shiffman, Dov, Rowland, C.M., Rudi G J Westendorp, Charles M. Rowl, Jukema, J.W., Sacks, F.M., Sattar, N., Jukema, J. Wouter, Catanese Joseph J., Ford, I., Catanese, Joseph J., Todd G Kirchgessner, Trompet Stella, Judy Z Louie, Sattar Naveed, Packard Christopher J., Louie, J.Z., Slagboom, P.E., Shiffman Dov, James J Devlin, Kirchgessner, Todd G., de Craen, Anton J. M., Buckley, Brendan M., Kirchgessner Todd G., Joseph J. Catanese, J. Wouter Jukema, Devlin, J.J., Westendorp, R.G.J., Packard, C.J., Frank M Sacks, Stott David J., Kirchgessner, T.G., Packard, Christopher J., Devlin James J., de Craen, A.J.M., Rowland Charles M., Jukema J. Wouter, J Wouter Jukema, Eline Slagboom, Iakoubova, O.A., Sattar, Naveed, Olga A Iakoubova, Christopher J Packard, James J. Devlin, Anton J. M. De Craen, Stott, David J., Slagboom P. Eline, Christopher J. Packard, Brendan M Buckley, Stott, D.J., Todd G. Kirchgessner   +88 more
core   +1 more source

Benchmark of Open‐Access Star‐Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies

Clinical Pharmacology &Therapeutics, EarlyView.
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star‐allele callers have been developed for this purpose of identifying the correct star alleles ...
Marc B. Gros‐La‐Faige, Emmanuelle Génin, Anthony F. Herzig   +2 more
wiley   +1 more source

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data

Clinical Pharmacology &Therapeutics, EarlyView.
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat, Haribhau Kangne, Rasmus Jansson‐Löfmark, Jens K. Hertel, Amin Rostami‐Hodjegan, Ida Robertsen, Aleksandra Galetin   +6 more
wiley   +1 more source